A futility study of minocycline in huntington's disease

Movement Disorders

Volumn 25, Issue 13, 2010, Pages 2219-2224

  Cudkowicz, Merit ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trial; Futility designs; Huntington's disease; Minocycline

Indexed keywords

MINOCYCLINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; NULL HYPOTHESIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

ACTIVITIES OF DAILY LIVING; ADULT; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNTINGTON DISEASE; MALE; MEDICAL FUTILITY; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME;

EID: 78649369122     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23236     Document Type: Article

References (16)

1. Marshall F, Shoulson I. Huntington's disease: clinical features and therapy. In: Watts R, Kollers W, editors. Movement disorders: neurologic principles and practice. New York: McGraw HIll; 1997. p.491-502.
2. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspaseindependent and -dependent mitochondrial cell death pathways in models of Huntington's disease. PNAS 2003;100:10483-10487.
3. Zhu S, Stavrovskiaya I, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
4. Chen M, Ona C, Li M, et al. Minocycline inhibits caspase-1 and caspase-2 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Med 2000;6:797-801.
5. Stack E, Smith K, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006;1762:373-380.
6. Smith D, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003;54:186-196.
7. Friedlander R. Apoptosis and caspases in neurodegenerative diseases. New Engl J Med 2003;348:1365-1375.
8. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142.
9. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
10. Huntington Study Group (Kieburtz K, principal author). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
11. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996;52:1324-1333.
12. Little R, Rubin D. Statistical analysis with missing data. Hoboken: John Wiley and Sons, Inc.; 2002.
13. Huntington Study Group. Minocycline safety and tolerability in Huntington's disease. Neurology 2004;63:547-549.
14. Gordon PH, Moore DH, Florence JM, et al. Results of the phase III randomized controlled trial of minocycline in ALS. Neurology 2007;68(suppl 1):A90-A91.
15. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
16. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke. An open-label, evaluator-blinded study. Neurology 2007;69:1404-1410.